Further understanding of the precise immune tumor microenvironment associated with TEM8/ANTXR1 upregulation in high grade neuroendocrine carcinoma, well differentiated neuroendocrine tumors, and other associated tumor types is key to not only using SVV-001 to target these diseases, but also to developing other novel agents that could be used in combination with SVV-001. Here, ANTXR1 is linked to neuroendocrine neoplasm.